Session date: 
Wednesday, May 27, 2015 - 7:00am to 8:00am
Location: 
ISTH Webinar Library Once a Month
Carrboro, NC 27510
United States
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Please login or register to take this course.
Program Description: 

Through its educational arm, the ISTH Academy, the International Society on Thrombosis and Haemostasis (ISTH) has begun hosting a series of webinars on practical thrombosis and haemostasis issues that scientists and physicians frequently confront. These webinars will allot time for participants to ask questions and will cover the latest information on relevant topics.

  Moderator: Raj Kasthuri, MD

  John Eikelboom, MD 

Combining antiplatelet therapy with anticoagulants

   Laura Mauri, MD

Dual Anti-platelet Therapy: Current management strategies following cardiac stent placement

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Medical College of Wisconsin and International Society on Thrombosis and Haemostasis. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
 
Designation of Credit Statement:
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
More information and online registration:  http://www.prolibraries.com/isth/
 
 

 
Target audience: 

Presentation is attended for basic scientists and clinicians, including trainees, interested in antiplatelet and anticoagulant therapy.

Learning objectives: 

At the conclusion of this activity, I will be able to:

  1. Describe the rationale for combining antiplatelet and anticoagulant therapy
  2. Differentiate between the clinical settings in which the combination is of proven and unproven benefit
  3. Justify the implications of the currently available evidence for clinical practice and future research
  4. Understand new developments in coronary device and concomitant pharmacologic strategies to prevent ischemic complications in patients treated with coronary stents
  5. Understand results from recent clinical trials regarding antiplatelet therapy in patients treated with coronary stents
  6. Identify examples of observational data and randomized trial analysis as methods to compare treatment strategies
Faculty & credentials: 
Planning Committee:
Yukio Ozaki
Geoff Barnes
Chris Ward
Cary Clark
Stephen Watson
 
 
Presenter:
John Eikelboom, MD
Laura Mauri, MD
 
 
 
All persons in control of content have NO relevant financial relationships to disclose with the exception of the following persons:  
 

Name

Company

Role

Chris Ward, MD

Bayer

Advisory Board, Speaker

Pfizer, BMS

Advisory Board, Speaker

Boehringer-Ingelheim

Advisory Board, Speaker

Alexion

Advisory Board

Medimark

Steering Committee Member, Speaker

Geoff Barnes

BMS, Pfizer, Blue Cross Blue Shield of Michigan

Primary Investigator & Co-Investigator

Yukio Ozaki

Sysmex

Advisory Board

Raj Kasthuri

Bayer Healthcare, GSK

Consultant

John Eikelboom

Astra-Zeneca, Bayer, BMS, Pfizer, Janssen, Sanofi-Aventis, Eli-Lilly, Boehringer-Ingelheim, Daiichi, GSK

Consultant

Laura Mauri

Abbott, Boston Scientific, Cordis, Medtronic Eli Lilly, Daiichi Sankyo, BMS, Sanofi-Aventis, Biotronik, Medtronic, St. Jude Medical

PI, Consultant


In accordance with the ACCME®  Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved

CME Coordinator Contact Information

Name: 
Cary Clark
Phone number: 
+1 (919) 929-3807